Blueprint Medicines Stock News

The European Commission approves Blueprint Medicines' (BPMC) Ayvakyt for treating adult patients with advanced systemic mastocytosis.

Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Blueprint Medicines Corporation (NASDAQ:BPMC) shares, rose in value on Friday, 03/11/22, with the stock price up by 0.11% to the previous day’s close as strong demand from buyers drove the stock to $57.10. Actively observing the price movement in the last trading, the stock closed the session at $57.04, falling within a range of $57.00 … What Analysts Were Expecting After Blueprint Medicines Corporation (NASDAQ: BPMC) rose 0.11% Read More »

Since the coronavirus pandemic began in early 2020, the FDA's plate has been full with reviews of COVID-19 vaccines and treatments. That has put the approval of many other drugs and therapies on the

The trading price of Blueprint Medicines Corporation (NASDAQ:BPMC) closed higher on Tuesday, March 08, closing at $55.55, 2.68% higher than its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << Traders who pay close attention to intraday price movement should know that it fluctuated between $53.26 … Blueprint Medicines Corporation’s Stock Gains 2.68%, But It May Still Be Worth Investing In. Read More »

Since the coronavirus pandemic began in early 2020, the FDA's plate has been full with reviews of COVID-19 vaccines and treatments. That has put the approval of many other drugs and therapies on the

CAMBRIDGE, Mass., March 8, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced plans to present new clinical and preclinical data for multiple programs across its precision therapy portfolio at the American Association for Cancer Research (AACR) Annual…

Over the past 3 months, 5 analysts have published their opinion on Blueprint Medicines (NASDAQ:BPMC) stock. These analysts are typically employed by large Wall Street banks and tasked with understandi

Over the past 3 months, 5 analysts have published their opinion on Blueprint Medicines (NASDAQ: BPMC ) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company''s business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 1 2 0 0 Last 30D 0 0 0 0 0 1M Ago 1 0 2 0 0 2M Ago 1 1 0 0 0 3M Ago 0 0 0 0 0 In the last 3 months, 5 analysts have offered 12-month price targets for Blueprint Medicines. The company has an average price target of $97.8 with a high of $120.00 and a … Full story available on Benzinga.com

Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71, compared to year-ago quarter

Blueprint Medicines Corporation (NASDAQ: BPMC ) and Proteovant Therapeutics have entered a strategic collaboration for targeted protein degrader therapies . The collaboration will bring Proteovant''s Artificial Intelligence (AI)-enhanced targeted protein degradation (TPD) platform and Blueprint Medicine''s precision medicine expertise to discover novel targeted protein degraders. The companies will … Full story available on Benzinga.com

Blueprint Medicines (BPMC) and Proteovant Therapeutics will collaborate on protein degrader therapies and advance up to two candidates into development.The collaboration will…

Blueprint Medicines Corporation (NASDAQ: BPMC) and Proteovant Therapeutics today announced a strategic collaboration to advance novel targeted protein degrader therapies to address important areas of medical need. Targeted protein degradation harnesses the body''s natural protein disposal system and offers the potential to develop new medicines that target historically difficult-to-drug proteins that play an important role in causing serious diseases.

Blueprint Medicines (BPMC) misses on earnings while revenue beat estimates for the fourth quarter of 2021. Stock down.

Shares of Blueprint Medicines (BPMC) are down in morning trading after at least two Street firms weighed in on the company Q4 2021 results released Wednesday.